Is the AIDS Terminator Coming? Gilead's new HIV prevention drug clinical data disclosure shows an effective rate of nearly 100%, requiring only 2 doses per year
芊芊551
发表于 7 天前
130
0
0
On September 12 local time, the results disclosed by GILD. NASDAQ showed that Lenacapavir, a new drug for pre exposure prevention of AIDS virus (HIV) (PrEP), showed high effectiveness again. Among the 2180 participants in the Lenacapavir group, there were only 2 new cases, and 99.9% of the participants were not infected with HIV, resulting in a relative risk reduction of 96%; There were 9 new cases among the 1087 subjects in the control group. As of the close of the day, Gilead Science closed up 2.74%, approaching a historical high.
Under the influence of Lenacapavir's amazing clinical data, on September 13, the stock price of Aidi Pharmaceutical (688488. SH), a Chinese manufacturer of AIDS drugs, plummeted. As of press release, Aidi Pharmaceutical had dropped by more than 15%.
As for the news of Gilead AIDS prevention drugs and stock price fluctuations, the investor relations department of Aidi Pharmaceutical said that Gilead had also released the stage results in June this year, and said that "some people may think that if the drug is completely effective, it will not completely curb the HIV patient population, and the number of new patients will decrease a lot."
However, according to the above-mentioned individuals, there are currently oral medications available in China for this indication, which have been on the market for several years. However, the number of new HIV patients in China has not changed significantly. According to public information, there are currently four domestically produced new HIV drugs on the market, among which Eddie Pharmaceutical has two, namely Ainoviline tablets (trade name: iBond) and Ainomitinib tablets (trade name: Fubond).
Gilead is the dominant force in the field of anti HIV drugs. At present, Gilead's AIDS treatment related drug products include Biktarvy, Complex/Eviplera, Descovy, Genvoya, Odefsey, Stribild, Truvada, etc. Biktarvy is the world's best-selling AIDS treatment drug.
The new anti HIV drug Lenacapavir is an HIV-1 capsid inhibitor that mainly inhibits HIV-1 replication by stabilizing the HIV genetic material and the conical shell of essential enzymes, thereby preventing the breakdown of the capsid in infected cells. Lenacapavir is unique in that at present, most anti HIV drugs only act at one stage to prevent virus replication, but Lenacapavir can play an inhibitory role in the whole life cycle of HIV. According to Gilead's information, Lenacapavir has no known cross resistance with other existing drug categories and only needs to be administered twice a year.
Linda Gal Bekker, director of Desmond Tutu HIV Center at the University of Cape Town, South Africa and former president of the International Society for AIDS, said: "Although we know that traditional HIV prevention programs are very effective when taken by prescription, Lenacapavir, which only needs to be administered twice a year, can not only improve drug compliance, but also help solve the stigma and discrimination that some people may face when taking or storing oral PrEP drugs."
The above data comes from the mid-term analysis results of a key phase 3 trial called PURPOSSE 2. This is a randomized, double-blind, multicenter phase 3 study to evaluate the safety and effectiveness of twice yearly subcutaneous injection of lenacapavir as a pre exposure prophylaxis (PrEP) therapy, compared with the background incidence rate of HIV (bHIV) and once daily oral therapy Truvada. Truvada is an antiviral drug developed by Gilead and has been approved by the US FDA for PrEP for over ten years.
Gilead introduced that the PURPOSSE project is the most comprehensive and diverse HIV prevention trial project in history, including five global HIV prevention trials. In June this year, Gilead also disclosed the interim results of a PURPOSE trial. The data showed that Lenacapavir's effective rate of prevention before female HIV exposure (PrEP) reached 100%. Gilead said at that time that it was expected that another key trial, PURPOSE 2, would obtain results by the end of 2024 or the beginning of 2025.
Gilead expects to submit a listing application for Lenacapavir to global regulatory authorities by the end of 2024 to support its launch in 2025, becoming the first twice yearly HIV prevention option.
(Li Aohua, a reporter from Time Finance, is integrated from Wuming Kant's official WeChat official account, the Associated Press of Finance, Time Finance, and 21 Finance)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- September Curse ": The US stock market felt it on its first day!
- Buying a car and getting a plane! The pre-sale price of Xiaopeng Huitian Flying Car's' Land Carrier 'at the end of the year will not exceed 2 million yuan
- Are bulk commodities at the 'turning point'? Goldman Sachs' latest perspective is here!
- Apple removes iPhone 15 Pro series from official website! Apple's first AI phone has received negative reviews from foreign media!
- The biggest iPhone 16 in history is here! Add quantity without adding price
- Disney's plan to expand consumer goods overseas: Nearly 70 Asia Pacific partners engage in cross-border business
- The Hong Kong Stock Exchange will undergo new changes! Did Xiaomi SU7 smoke in the accident? Response has arrived! Microsoft announces up to $60 billion buyback plan
- Alibaba, Wal Mart and Kwai are here... The highlights of Global Digital Trade Expo are the first to see
- Will the recession come? Americans are in the "richest" period in history thanks to real estate and stocks!
- What is the value of gold in the world? A new record has arrived: $20 trillion!
-
【世界市場】1、納指は0.04%、ダウは0.70%、スタンダードは0.19%下落した。2、英偉達は2%超上昇し、美光科技の株価は10%超上昇した。3、ナスダック中国の金龍指数は2.80%、蔚来は5%近く下落した。4、国際原油価格は ...
- 虚空一粒沙2017
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
世界的な整形外科大手のシュレックはこのほど、ニューラルテクノロジー会社のNico Corporationの買収を完了したと発表した。紹介によると、Nicoは私営会社で、腫瘍と脳内出血(ICH)手術のための系統的な低侵襲手術 ...
- 就放荡不羁就h
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
AP通信9月27日、インテルは今月中旬に発表された重大な業務調整に加え、近日中にクアルコムに買収合併される可能性があるとの情報を伝えていることを明らかにした。 しかし、ウォール街のほとんどのアナリストは、 ...
- 什么大师特
- 前天 16:13
- 支持
- 反对
- 回复
- 收藏
-
9月26日、Meta Platformsは巨額の資金を投じてスターを招待していることを明らかにした。Metaは水曜日、俳優のオスカー・フィーナ(Awkwafina)、ジョン・セナ(John Cena)、ジュディ・デンチ(Judi Dench)、クリ ...
- hecgdge4
- 3 天前
- 支持
- 反对
- 回复
- 收藏